# Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

> **NCT03927690** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 91 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** LKA651
- **DRUG:** Lucentis

## Key facts

- **NCT ID:** NCT03927690
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-24
- **Primary completion:** 2022-06-17
- **Final completion:** 2022-08-31
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2024-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03927690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03927690, "Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03927690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*